InvestorsHub Logo
Followers 89
Posts 18987
Boards Moderated 4
Alias Born 11/05/2005

Re: Preciouslife1 post# 4202

Tuesday, 09/27/2016 1:16:12 PM

Tuesday, September 27, 2016 1:16:12 PM

Post# of 5468
From Briefing.com

PPHM: Peregrine Pharma presents preclinical study data demonstrating that PS-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of multiple checkpoint targeting agents (0.42)
Peregrine's Michael J. Gray, Ph.D., the study's lead scientist, presented the study findings at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference September 25-28, 2016, in New York City.
Data showed that eight of the ten (80%) animals receiving the preclinical bavituximab equivalent (ch1N11) combined with anti-PD-1 and anti-LAG3 therapies experienced complete tumor regressions, whereas there were no animals (0/10) in the anti-PD-1 and anti-LAG3 combination treatment arm that had a complete regression.
Additional data demonstrated that the Triple Combination featuring ch1N11 led to a 99% reduction in total tumor volume at the interim analysis point (Day 25) across all animals as compared to the control arm.
In addition, the Triple Combination showed a statistically significant increase in tumor growth inhibition (TGI) as compared to the anti-PD-1 and anti-LAG3 combination treatment (99% vs. 62%; p < 0.05).

Bull-markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria .. Sir John Templeton
Make your Life a Mission .... NOT an Intermission. † §|PL1|§

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.